But her underlying point isn't totally invalid —
the furor over drug price hikes like Mylan's is forcing legislators and private companies alike to finally confront the issue head - on, and highlighting just how difficult the disparate and largely opaque American medical financing system makes it to address these problems in a serious way.
A psychiatrist whose failure to disclose
drug company income contributed to a
furor over conflicts of interest in biomedical research has just received his first National Institutes of Health (NIH) grant in 3 years.